INTELLIA THERAPEUTICS INC
NASDAQ: NTLA (Intellia Therapeutics, Inc.)
Last update: 2 hours ago15.67
0.47 (3.09%)
| Previous Close | 15.20 |
| Open | 15.53 |
| Volume | 8,849,172 |
| Avg. Volume (3M) | 6,377,575 |
| Market Cap | 2,189,447,936 |
| Price / Sales | 22.07 |
| Price / Book | 2.72 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Operating Margin (TTM) | -726.57% |
| Diluted EPS (TTM) | -5.23 |
| Quarterly Revenue Growth (YOY) | -42.50% |
| Total Debt/Equity (MRQ) | 15.29% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -377.15 M |
| Levered Free Cash Flow (TTM) | -150.18 M |
| Return on Assets (TTM) | -30.12% |
| Return on Equity (TTM) | -57.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Intellia Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.60 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.98% |
| % Held by Institutions | 97.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ark Investment Management Llc | 31 Mar 2026 | 14,509,247 |
| Regeneron Pharmaceuticals, Inc. | 31 Mar 2026 | 3,702,995 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 2,346,317 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BHANJI MUNA | 12.89 | - | 9,200 | 118,588 |
| CHASE WILLIAM J | 12.89 | - | 9,200 | 118,588 |
| COHEN FRED E | 12.89 | - | 9,200 | 118,588 |
| GOFF BRIAN | 12.89 | - | 9,200 | 118,588 |
| GOODMAN JESSE | 12.89 | - | 9,200 | 118,588 |
| KERESTY GEORGIA | 12.89 | - | 9,200 | 118,588 |
| VERWIEL FRANK | 12.89 | - | 9,200 | 118,588 |
| Aggregate Net Quantity | 64,400 | |||
| Aggregate Net Value ($) | 830,116 | |||
| Aggregate Avg. Buy ($) | 12.89 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BHANJI MUNA | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| CHASE WILLIAM J | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| COHEN FRED E | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| GOFF BRIAN | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| GOODMAN JESSE | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| KERESTY GEORGIA | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| VERWIEL FRANK | Director | 09 Jun 2026 | Acquired (+) | 9,200 | 12.89 | 118,588 |
| Date | Type | Details |
|---|---|---|
| 27 Apr 2026 | CNBC | Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |